Calcified Tissue International最新文献

{"title":"Hip Structural Analysis and Multiple Fragility Fractures: Evidence from a Large Cross-Sectional Clinical Cohort.","authors":"Hamzah Amin, Ajmal Elhani, Amaan Shaffi, Marwan Bukhari","doi":"10.1007/s00223-026-01625-4","DOIUrl":"10.1007/s00223-026-01625-4","url":null,"abstract":"<p><p>Hip structural analysis parameters (HSAP) are associated with hip fracture risk, but associations with multiple fragility fracture phenotypes remain poorly characterised. We analysed 11 DXA-derived HSAP in patients referred between June 2004 and November 2019. Five mutually exclusive fracture phenotypes were defined: no fracture, single hip fracture, single non-hip fracture, multiple non-hip fractures, and multiple fractures including at least one hip fracture. Separate multinomial logistic regression models were fitted for each HSAP reported as odds ratio (OR) per standard deviation increase, adjusted for FRAX covariates and left femoral BMD. Benjamini-Hochberg false discovery rate correction was applied across all tests. A right-hip sensitivity analysis assessed bilateral consistency. 35,647 patients were included (mean age 64.5 years, 82% female). Of 13,777 (38.6%) with a fragility fracture, 1044 (2.9%) had a single hip fracture, 9723 (27.3%) a single non-hip fracture, 2268 (6.4%) multiple non-hip fractures, and 742 (2.1%) multiple fractures including at least one hip fracture. After multiple testing correction, no meaningful associations were observed for isolated hip or non-hip fracture phenotypes. Multiple fractures including at least one hip fracture were independently associated with greater hip axis length (OR 1.44, 95% CI 1.28 to 1.63), neck diameter (OR 1.24, 95% CI 1.11 to 1.38), and centre of mass to upper neck margin distance (OR 1.35, 95% CI 1.21 to 1.51). HSAP were significantly associated with multiple fractures including at least one hip fracture rather than isolated fracture phenotypes, potentially reflecting local structural vulnerability and broader biomechanical instability.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Association to Treatment Threshold: Interpreting Burosumab Dose and HRQoL in Pediatric X-Linked Hypophosphatemia.","authors":"Ercan Yılmaz, Zeynep Yamancan Yılmaz","doi":"10.1007/s00223-026-01623-6","DOIUrl":"https://doi.org/10.1007/s00223-026-01623-6","url":null,"abstract":"","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trabecular Bone Score has Limited Ability to Discriminate Fragility Fractures in Postmenopausal Women with Osteopenia: A Danish Case-Control Study.","authors":"Vivi-Nelli Mäkinen, Amalie Lyngberg, Anne Sophie Sølling, Torben Harsløf, Bente L Langdahl","doi":"10.1007/s00223-026-01621-8","DOIUrl":"https://doi.org/10.1007/s00223-026-01621-8","url":null,"abstract":"<p><strong>Introduction: </strong>Most fragility fractures occur in women with osteopenia, defined by a BMD T-score between - 1.0 and - 2.5. Although bone mineral density (BMD) is used to estimate fracture risk, bone strength is determined by both bone mass and quality. Degraded trabecular bone score (TBS) has been shown to be independently associated with increased fracture risk. Notably, some individuals with osteopenia have degraded TBS despite only modest reductions in BMD. We aimed to investigate the potential value of TBS in discriminating between postmenopausal women with osteopenia with and without fragility fractures.</p><p><strong>Methods: </strong>We conducted a retrospective case-control study (1:1) of women with osteopenia at Aarhus University Hospital. Cases had experienced a fragility fracture and were identified through attendance in our Fracture Liaison Service between 01.05.2022-29.04.2024 Controls were referrals for DXA with clinical risk factors. Cases and controls were matched on age (± 5 years).</p><p><strong>Results: </strong>We matched 305 cases with 305 controls. TBS was significantly lower in cases (1.28 IQR(1.20;1.35) vs.1.31 (1.23;1.37), p < 0.01). No differences were found in BMD at any site. Each SD decrease in TBS was associated with a 24% greater odds ratio of a fracture (OR 1.24, 95% CI 1.05;1.48; p < 0.01). Adjusting for weight, height and total hip BMD, the association between TBS and fracture was nonsignificant (p = 0.12). ROC curve analysis demonstrated an AUC of 0.45, TBS failing to discriminate between cases and controls.</p><p><strong>Conclusion: </strong>TBS was significantly lower in women with a fragility fracture compared nonfractured controls but showed limited clinically relevant discriminatory performance between women with and without fractures in our Danish cohort.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Improvement of Bone Healing by Combined Treatment with Selective Androgen and Estrogen Receptor Modulators in Female and Male Rats.","authors":"Marina Komrakova, Fabian Nicolai Brunnert, Christian Anders, Kai Oliver Böker, Arndt Friedrich Schilling, Paul Jonathan Roch, Daniel Bernd Hoffmann, Wolfgang Lehmann, Stephan Sehmisch","doi":"10.1007/s00223-026-01609-4","DOIUrl":"https://doi.org/10.1007/s00223-026-01609-4","url":null,"abstract":"","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13653816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Water Fluoridation Risks or Benefits: Summary of the Symposium Presented During the Enamel 11 Meeting Held in Paris France.","authors":"Sylvie Babajko, Marilia Buzalaf, Jean-Baptiste Fini, Pamela Den Besten","doi":"10.1007/s00223-026-01601-y","DOIUrl":"https://doi.org/10.1007/s00223-026-01601-y","url":null,"abstract":"","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical Primer on Computer Vision.","authors":"Jon Parkinson, Claudia Lindner","doi":"10.1007/s00223-026-01620-9","DOIUrl":"10.1007/s00223-026-01620-9","url":null,"abstract":"<p><p>Computer vision is a rapidly evolving field within computer science that focuses on extracting meaningful information from digital images. In medical imaging, computer vision techniques such as object detection, classification, and segmentation are essential for analysing complex anatomical structures. This primer provides an overview of computer vision concepts and methods, highlighting both traditional approaches and modern machine learning techniques. Landmark detection and shape modelling are also discussed as these are particularly relevant for musculoskeletal imaging. Challenges associated with applying computer vision in clinical practice are examined. This includes considerations such as data limitations, domain shift, and the need for robust validation. Finally, future directions for integrating computer vision into osteoporosis research and clinical workflows are explored, emphasising the importance of explainability, fairness, and adherence to guiding principles for trustworthy clinical tools.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Morbidity and Mortality in Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis.","authors":"Deep Dutta, Kunal Mahajan, Ashima Mittal, Oscar R Rivera, Bhavya Raja Gopal Yarlagadda, A B M Kamrul-Hasan","doi":"10.1007/s00223-026-01617-4","DOIUrl":"10.1007/s00223-026-01617-4","url":null,"abstract":"<p><p>Chronic hypoparathyroidism (HypoPT) may increase cardiovascular risk, yet current care rarely includes structured cardiovascular assessment. This systematic review and meta‑analysis aimed to quantify the association of chronic HypoPT with major cardiovascular events. Electronic databases and registries were searched from their inception through 10 June 2026 to identify controlled cohort studies of adults with chronic HypoPT and non-HypoPT comparators that reported cardiovascular outcomes. Random‑effects meta‑analyses (for hazard ratios [HRs]) were conducted for the primary and secondary outcomes using R. Data from nine cohort studies (N=134, 598; HypoPT: 28, 625; controls: 105, 973) were analyzed. HypoPT was associated with higher risk of myocardial infarction (MI) (HR1.19, 95%CI1.06, 1.35; I²=0%). HypoPT was associated with higher occurrence of heart failure (HF) [HR 1.46(95%CI: 1.08, 1.96); I²=83.5%; P=0.012] which lost its significance on prediction-interval analysis (PIA) (95%CI: 0.62, 3.42). HypoPT had higher occurrence of arrhythmias [HR1.45(95%CI: 1.19, 1.76); I²=64.9%; P=0.0002] which lost its significance on PIA (95%CI: 0.87, 2.43). HypoPT had higher occurrence of stroke [HR 1.24(95% CI: 1.05, 1.46); I²=46.9%; P =0.009] which lost its significance on PIA (95%CI: 0.85, 1.81). HypoPT had higher all-cause mortality [HR1.40(95%CI: 1.07, 1.84); I²=80.9%; P = 0.015] which lost its significance on PIA (95% CI: 0.62, 3.15). Chronic HypoPT was associated with a higher pooled hazard of MI. Pooled associations with HF, arrhythmias, stroke, composite cardiovascular disease, CKD, and all-cause mortality were imprecise and heterogeneous, with prediction-intervals that included the null.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Romosozumab Prescribing in Relation to Cardiovascular Disease History in Japan: A Nationwide Claims Database Study.","authors":"Yuki Fujita, Katsuyasu Kouda, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Sumito Ogawa, Masayuki Iki","doi":"10.1007/s00223-026-01613-8","DOIUrl":"https://doi.org/10.1007/s00223-026-01613-8","url":null,"abstract":"<p><p>Concerns regarding the cardiovascular safety of romosozumab have led to regulatory restrictions and precautionary guidance worldwide. In Japan, although a history of myocardial infarction or stroke is not a formal contraindication, physicians are cautioned to avoid prescribing romosozumab to patients who have experienced these events within the previous year. How this caution is reflected in real-world clinical practice remains insufficiently described. We conducted a nationwide descriptive study using the National Database of Health Insurance Claims of Japan, which covers nearly the entire Japanese population. Patients who initiated romosozumab between March 2019 and March 2023 were identified. Cardiovascular disease (CVD) history was defined as documented myocardial infarction or stroke within 360 days prior to initiation. For comparison of prescribing patterns, users of other anti-osteoporosis medications (AOMs) were also examined. Temporal trends in the prevalence of CVD history and associations with treatment discontinuation were assessed. A total of 311,585 patients initiated romosozumab during the study period. CVD history was present in 11.7% of men and 7.9% of women at initiation. These proportions were lower than those observed among other AOM users (16.4-17.6% in men, 8.9-11.5% in women) and declined across successive fiscal years. Patients with CVD history had higher probabilities of treatment discontinuation, particularly among women. This nationwide claims-based study provides real-world romosozumab prescribing patterns in relation to CVD history in Japan. Continued efforts to enhance awareness and adherence to cardiovascular risk precautions are warranted until the cardiovascular safety profile of romosozumab is more clearly established.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Objective Physical Performance Predicts 10-Year Fracture Risk Without Densitometry in Older Men and Women: Development and Head-to-Head Comparison with FRAX in MrOS and SOF.","authors":"Filipe R Carvalho, Paulo J Gavaia","doi":"10.1007/s00223-026-01618-3","DOIUrl":"https://doi.org/10.1007/s00223-026-01618-3","url":null,"abstract":"<p><p>FRAX estimates 10-year fracture probability from clinical risk factors and, for best performance, DXA-derived bone mineral density (BMD), limiting its use where densitometry is unavailable. We tested whether a five-variable, laboratory- and imaging-free model (age, body-mass index, grip strength, gait speed and chair-stand rate; M5) predicts incident fracture and how it compares with FRAX. In community-dwelling older men (Osteoporotic Fractures in Men Study, n = 5994; 73.7 years) and women (Study of Osteoporotic Fractures, n = 9704; 71.6 years) with baseline physical-performance measures and adjudicated incident major osteoporotic fracture (848 and 2522 events), M5 was developed by five-fold cross-validation; we assessed time-dependent AUC at 5, 10 and 15 years, calibration and decision-curve net benefit. Comparators were FRAX in men and a conservative FRAX-surrogate model (in-cohort clinical risk factors) in women, since individually linked, licensed FRAX scores were not available for SOF. In men, M5 discriminated fracture better than FRAX without BMD (10-year ΔAUC + 0.052, 95% CI + 0.023 to + 0.080) and did not differ significantly from FRAX with BMD (+ 0.029, - 0.005 to + 0.063) in this cross-validated, in-cohort comparison; adding BMD to M5 gave the highest discrimination. In women, M5 did not differ significantly from the FRAX-surrogate comparator (- 0.008, - 0.018 to + 0.002), and BMD-based models performed best. M5 was well calibrated (calibration slope 0.97-0.98) and gave higher (men) or equivalent (women) net benefit. Death was a major competing event (72.7% of men, 61.4% of women) but changed 10-year incidence by ~ 1 percentage point. A five-variable, laboratory- and imaging-free model incorporating physical performance stratifies 10-year fracture risk at least as well as FRAX without BMD in men, without requiring imaging, laboratory tests or fracture history. Because M5 was developed within these cohorts whereas FRAX is an external, fixed algorithm, part of this margin reflects development asymmetry; the findings are promising but require external validation before clinical use, and do not replace measured BMD.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation and Characterization of an Osteoclastic Cell Model of Gaucher's Bone Disease.","authors":"Juan-David Patiño-Salazar, Juan Diego Gutiérrez-Ávila, Sara Heredero-Jimenez, Eduardo Martín-Guerrero, Núria Martínez-Gil, Mónica Cozar, Diana Ovejero, Xavier Nogués, Laura Cinque, Juan A Ardura, Arancha R Gortazar, Daniel Grinberg, Susanna Balcells, Natalia Garcia-Giralt, Raquel Rabionet","doi":"10.1007/s00223-026-01616-5","DOIUrl":"https://doi.org/10.1007/s00223-026-01616-5","url":null,"abstract":"<p><p>Gaucher disease (GD) is caused by recessive mutations in the GBA1 gene (Glucosylceramidase beta 1) generating lysosomal accumulation of glucosylceramides. Bone phenotypes related to GD include Erlenmeyer flask deformity, osteosclerosis, osteonecrosis, osteopenia, and bone pain. Lysosomes modulate osteoclast differentiation, playing a fundamental role in osteoclastogenesis and bone resorption. However, the role of GBA1 mutations in the osteoclast function remains poorly understood. We aimed to generate and characterize an in vitro osteoclast cell model of GD. The Gba1 gene was knocked out with CRISPR/Cas9 in the murine macrophage cell line RAW264.7. One RAW-Gba1KO clone displaying no GBA1 enzymatic activity was selected. Non-edited RAW264.7 cells were used as controls (wt). Expression of osteoclast biomarkers, Rank, Trap, Nfatc1, and pro-cathepsin K/cathepsin K as well as activity of TRAP protein and bone resorption were assessed. RAW-Gba1KO cells showed reduced expression of the osteoclast differentiation markers Rank and Nfatc1, suggesting that osteoclast differentiation is delayed or impaired compared with wt cells. Despite this, KO cells exhibited higher expression of Trap and cathepsin K, indicating enhanced osteoclast activity. Functional assays confirmed this finding, showing significantly increased TRAP activity and bone resorption in KO cells during differentiation. Additionally, KO cells displayed elevated levels of cathepsin K and pro-cathepsin K, particularly before differentiation, which may contribute to the increased TRAP activation. In conclusion, lack of Gba1 activity induced changes in our osteoclast model which enhanced its bone resorption potential, demonstrating a major intrinsic osteoclastic defect in Gaucher disease of bone.</p>","PeriodicalId":9601,"journal":{"name":"Calcified Tissue International","volume":"117 1","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}